Skip to main content

Latest News

Seres Therapeutics, Inc. Announces FDA Orphan Drug Designation for SER-109 for the Prevention of Recurrent Clostridium Difficile Infection in Adults

August 21, 2015

Diversity by Design

Seres Therapeutics has built a proprietary discovery and design platform that enables us to understand the dysbiosis associated with specific diseases.


Product Pipeline

SER-109, our lead development candidate for the prevention of Clostridium difficile infection, has been designated by the FDA as a Breakthrough Therapy.


Clinical Trials

The ECOSPORTM Phase 2 clinical study is focused on the safety and efficacy of our Ecobiotic® drug, SER-109, an investigational microbiome therapeutic orally delivered as a capsule.


Back to top